Joseph N. DiStefano is the Inquirer's business columnist and reporter

Latest Stories

Hahnemann creditors want emergency department shut down next week

Most Hahnemann admissions come through its emergency department, so shutting the ER would rapidly reduce its patient population toward zero.

Hahnemann will stop admitting patients through ER July 17; Main Line could take 40 residents

Hahnemann University Hospital will stop admitting patients to the hospital through the emergency department. The ER will remain open but patients who need more advanced care will be stabilized and transferred.

Hahnemann’s demise should not be a surprise to any politicians in Philly

When the for-profit Tenet chain put Hahnemann up for sale two years ago, nobody else offered to buy it. It had lost money for more than a decade.

Column

Accused sex trafficker Jeffrey Epstein’s old boss says he knows where the mystery millions came from

From his prison cell at Fort Dix, convicted fraudster Steven Hoffenberg began a campaign to expose his former assistant, Presidential friend and accused sex trafficker Jeffrey Epstein, of keeping stolen millions. Epstein's lawyers deny it all.

Trump requested, Lockheed Martin delivered: Chesco helicopter plant to stay open

Lockheed Martin's Sikorsky helicopter plant in Coatesville, which makes the Marine One helicopters that fly President Trump around, will stay open an extra year, saving 465 jobs for the time being

Philly area’s biggest bank writes down millions in bad loans to refinery, health-care facility

Shares of WSFS Financial Corp. dropped more than 4 percent in morning trading, slipping below $40 for the first time in a month.

Column

Incyte, buoyed by former DuPonters, has rising revenues and a busy drug pipeline, but the payoff will take years, CEO says

Incyte spent $1.2 billion last year on research, more than half of its $1.9 billion in sales, a serious commitment for a drug firm.

Labor, state, and city officials seek last-ditch rescue funds for Hahnemann University Hospital

But people familiar with the hospital’s operations said privately that they see little chance of a last-ditch rescue due to Hahnemann’s antiquated or ineffective admissions, billing and other basic systems.

Blood pact: Roche-Spark deal deadline pushed back as regulators check impact on prices, availability

Roche had hoped to buy Philly-based Spark for $4.3 billion this Spring, but regulators' worries about what combining the companies' hemophilia programs might do has delayed approval, possibly into next year,and depressed the share price

Fast-growing home medical supplier AdaptHealth to raise cash, go public

Fast growing Plymouth Meeting medical distributor AdaptHealth, with sales of over half a billion dollars a year in oxygen machines and sleep-apnea equipment, will go public after raising millions in private-equity deal